Stay updated on Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.

Latest updates to the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page
- Check6 days agoChange DetectedThe page now shows a new revision label, Revision: v3.5.4, replacing the previous v3.5.3, indicating an internal update to the page version without changing publicly visible study information.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedRevision: v3.5.3 was added, replacing the previous v3.5.2. This reflects a small internal update to the page template rather than changes to the study details.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedRevision label updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check56 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check70 days agoChange DetectedRevision: v3.4.3 updated from v3.4.2.SummaryDifference0.0%

- Check99 days agoChange DetectedA new revision tag 'Revision: v3.4.2' was added, and the page no longer displays the previous government-funding notice or the earlier 'Revision: v3.4.1' text. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.